<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00758966</url>
  </required_header>
  <id_info>
    <org_study_id>NF-101</org_study_id>
    <nct_id>NCT00758966</nct_id>
  </id_info>
  <brief_title>Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder</brief_title>
  <official_title>A Proof-of-Concept, Multicenter, Randomized, Double-Blind, Parallel Study of Naltrexone Sustained-Release (SR) and/or Fluoxetine Therapy in the Treatment of Subjects With Obsessive-Compulsive Disorder (OCD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orexigen Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orexigen Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the combination of naltrexone SR and fluoxetine
      is more effective in treating the symptoms of obsessive-compulsive disorder (OCD)than either
      fluoxetine alone or naltrexone SR alone.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor Decision- Financial Considerations
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the mean change from baseline to Week 10 in total Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score between the combination treatment group versus fluoxetine alone and naltrexone SR alone</measure>
    <time_frame>Baseline to Week 10</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Obsessive-Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>NF (Naltrexone+Fluoxetine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naltrexone SR 32 mg and fluoxetine 60 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluoxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluoxetine 60 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naltrexone SR 32 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine 60 mg</intervention_name>
    <description>Two week titration followed by daily dosing of fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on fluoxetine 60 mg for an additional 6 weeks. Non-responders will have naltrexone SR 32 mg added to their therapy.</description>
    <arm_group_label>Fluoxetine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone 32 mg and fluoxetine 60 mg</intervention_name>
    <description>Two week titration followed by daily dosing of naltrexone SR 32 mg and fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on a daily dose of naltrexone SR 32 mg and fluoxetine 60 mg for an additional 6 weeks. Non-responders will have their daily dose adjusted to naltrexone SR 48 mg and fluoxetine 80 mg.</description>
    <arm_group_label>NF (Naltrexone+Fluoxetine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone SR 32 mg</intervention_name>
    <description>Two week titration followed by daily dosing of naltrexone SR 32 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on naltrexone SR 32 mg for an additional 6 weeks. Non-responders will have fluoxetine 60 mg added to their therapy.</description>
    <arm_group_label>Naltrexone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects, 18 to 60 years of age (inclusive)

          -  Outpatients with a current diagnosis of OCD that have received previous therapy

          -  Negative serum pregnancy test as screening in women of child-bearing potential

          -  If a woman of child-bearing potential, must agreed to use an acceptable and effective
             form of contraception

          -  No clinically significant abnormality on electrocardiogram (ECG)

          -  No clinically significant laboratory abnormality at screening

          -  Negative urine drug screen

          -  Must be considered reliable and possess a level of understanding that enables the
             subject to provide written informed consent and to comply with protocol procedures and
             schedule

        Exclusion Criteria:

          -  Diagnosis of substance dependence

          -  Diagnosis of substance abuse (except for nicotine and caffeine)

          -  Serious or unstable medical illnesses

          -  Lifetime history of bipolar disorder, schizophrenia or other psychosis, bulimia,
             anorexia nervosa, Pervasive Developmental Disorder (PDD), Asperger's Syndrome or the
             presence of antisocial or borderline personality disorder

          -  Diagnosis of tic disorder or Tourette's Syndrome

          -  Subjects diagnosed with impulse control disorder

          -  Known sensitivity or allergic reaction to either naltrexone or fluoxetine

          -  Any condition which in the opinion of the investigator or Sponsor makes the subject
             unsuitable for inclusion in the study

          -  Immediate family of investigators, study personnel or Sponsor representatives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey T Apter, MD, PA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Global Medical Institutes, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ward Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Summit Research Network, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vishaal Mehra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Clinical Trials</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Naresh P Emmanuel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carolina Clinical Research Services</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Bari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Synergy Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Riesenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atlanta Center for Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Teresa Pigott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida, Dept Of Psychiatry</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew W Goddard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Al Rivera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Community Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey S Simon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northbrooke Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zinoviy Benzar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brooklyn Medical Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Synergy Clinical Research</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Clinical Trials</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida, Department of Psychiatry</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Medical Institute, LLC</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooklyn Medical Institute</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Research Network, Inc.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Clinical Research Services</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northbrooke Research Center</name>
      <address>
        <city>Brown Deer</city>
        <state>Wisconsin</state>
        <zip>53223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2008</study_first_submitted>
  <study_first_submitted_qc>September 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2008</study_first_posted>
  <disposition_first_submitted>November 27, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>November 27, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 29, 2012</disposition_first_posted>
  <last_update_submitted>November 27, 2012</last_update_submitted>
  <last_update_submitted_qc>November 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OCD,</keyword>
  <keyword>naltrexone,</keyword>
  <keyword>fluoxetine,</keyword>
  <keyword>obsessive-compulsive disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

